We are excited to share with you the arrival of two new medications in the treatment arsenal to address Parkinson’s symptoms – RYTARY™ and DUOPA™
Some key facts about the two medications are:
o Approved by the Food and Drug Administration on January 8th.
o Manufactured by Impax Pharmaceuticals.
o Extended release formulation of carbidopa/levodopa.
o Developed to release more slowly over time, it will maintain the levodopa levels and provide greater treatment stability.
o Approved by the Food and Drug Administration on January 12th.
o Developed by AbbVie.
o Duopa™ is for those patients with advanced Parkinson Disease wearing off or dyskinesia who cannot manage symptoms with regular tablets and other oral medications.
o First and only treatment providing 16 continuous hours of carbidopa/levodopa for motor fluctuations in advanced PD.
Attached is the press release APDA will be releasing on the two medications. Please post it on your websites, social media, e-newsletters, and share with all your constituents as soon as possible.
If you have any further questions, please do not hesitate to contact Robin Kornhaber, Vice President of Programs and Services, 718-981-8001 ext 125, email@example.com.